Decitabine-induced DNA methylation-mediated transcriptomic reprogramming in human breast cancer cell lines; the impact of DCK overexpression

Decitabine (DAC), a DNA methyltransferase (DNMT) inhibitor, is tested in combination with conventional anticancer drugs as a treatment option for various solid tumors. Although epigenome modulation provides a promising avenue in treating resistant cancer types, more studies are required to evaluate...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Verona Buocikova, Silvia Tyciakova, Eleftherios Pilalis, Chara Mastrokalou, Maria Urbanova, Miroslava Matuskova, Lucia Demkova, Veronika Medova, Eleonora Marta Longhin, Elise Rundén-Pran, Maria Dusinska, Ivan Rios-Mondragon, Mihaela Roxana Cimpan, Alena Gabelova, Andrea Soltysova, Bozena Smolkova, Aristotelis Chatziioannou
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2022-10-01
Edice:	Frontiers in Pharmacology
Témata:	decitabine DNA methylation gene expression deoxycytidine kinase cytosine deaminase whole-genome analysis
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fphar.2022.991751/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!